Abbott Laboratories (ABT) Given Coverage Optimism Score of 0.09
News stories about Abbott Laboratories (NYSE:ABT) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave headlines about the healthcare product maker an impact score of 46.4809509445586 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- High-Level Earnings Momentum Keep Abbott Laboratories (ABT) a Buy (investorplace.com)
- Absolute Reports Fiscal 2018 First Quarter Financial Results (businesswire.com)
- Abbott Laboratories (ABT) Expected to Post Earnings of $0.73 Per Share (americanbankingnews.com)
- 7 Things AbbVie’s Top Executives Just Said That You’ll Want to Know (pantagraph.com)
- ETFs with exposure to Abbott Laboratories : November 9, 2017 (finance.yahoo.com)
Several research firms have recently weighed in on ABT. Cowen and Company restated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 17th. Stifel Nicolaus restated a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 21st. BidaskClub lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. BMO Capital Markets restated a “market perform” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Finally, Jefferies Group LLC restated a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research note on Thursday, August 3rd. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $56.81.
Shares of Abbott Laboratories (NYSE ABT) opened at $55.01 on Wednesday. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. The stock has a market cap of $96,255.23, a PE ratio of 22.95, a price-to-earnings-growth ratio of 2.07 and a beta of 1.06. Abbott Laboratories has a twelve month low of $37.38 and a twelve month high of $56.69.
Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 EPS. equities research analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a yield of 1.93%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 83.47%.
In other news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the completion of the sale, the insider now owns 113,426 shares of the company’s stock, valued at approximately $6,005,906.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jaime Contreras sold 52,700 shares of the company’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the sale, the insider now directly owns 58,739 shares of the company’s stock, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 211,763 shares of company stock valued at $11,476,131. 0.76% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/15/abbott-laboratories-abt-given-coverage-optimism-score-of-0-09.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.